0

524717

TITANBIO

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

TITAN BIOTECH LTD. Share Price Today

Investment Returns

Over 1 Month -2.78% Over 3 Months 14.71% Over 6 Months 104.40% Over 1 Year 416.61%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

TITAN BIOTECH LTD. fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 1,768.40
  • P/E Ratio (TTM) 64.53
  • Beta -0.11
  • Book Value / share 41.34
  • Return on equity 13.36%
  • EPS (TTM) 6.64
  • Dividend yield [-]%
  • Net profit/quarter (Cr) 6.56
info icon alternate text

TITAN BIOTECH LTD. Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 48.83
Operating Expense 40.66
Net Profit 6.56
Net Profit Margin (%) 13.43
Earnings Per Share (EPS) 1.59
EBITDA 11.82
Effective Tax Rate (%) 36.28
Particulars DEC 2025 (Values in Cr)
Revenue 56.51
Operating Expense 47.19
Net Profit 7.87
Net Profit Margin (%) 13.92
Earnings Per Share (EPS) 9.52
EBITDA 12.09
Effective Tax Rate (%) 25.47
Particulars SEP 2025 (Values in Cr)
Revenue 54.35
Operating Expense 46.46
Net Profit 6.86
Net Profit Margin (%) 12.62
Earnings Per Share (EPS) 8.30
EBITDA 10.65
Effective Tax Rate (%) 25.59
Particulars JUN 2025 (Values in Cr)
Revenue 46.50
Operating Expense 39.11
Net Profit 6.16
Net Profit Margin (%) 13.24
Earnings Per Share (EPS) 7.46
EBITDA 9.45
Effective Tax Rate (%) 24.04
Particulars MAR 2025 (Values in Cr)
Revenue 35.17
Operating Expense 31.52
Net Profit 3.77
Net Profit Margin (%) 10.71
Earnings Per Share (EPS) 4.56
EBITDA 5.95
Effective Tax Rate (%) 25.04
Particulars MAR 2026 (Values in Cr)
Revenue 206.19
Operating Expense 173.42
Net Profit 27.45
Net Profit Margin (%) 13.31
Earnings Per Share (EPS) 6.64
EBITDA 44.01
Effective Tax Rate (%) 28.11
Particulars MAR 2025 (Values in Cr)
Revenue 156.45
Operating Expense 135.99
Net Profit 18.27
Net Profit Margin (%) 11.67
Earnings Per Share (EPS) 22.11
EBITDA 29.34
Effective Tax Rate (%) 25.03
Particulars MAR 2024 (Values in Cr)
Revenue 164.07
Operating Expense 134.29
Net Profit 23.66
Net Profit Margin (%) 14.42
Earnings Per Share (EPS) 28.64
EBITDA 36.03
Effective Tax Rate (%) 24.96
Particulars MAR 2023 (Values in Cr)
Revenue 144.00
Operating Expense 117.83
Net Profit 21.02
Net Profit Margin (%) 14.59
Earnings Per Share (EPS) 25.44
EBITDA 31.47
Effective Tax Rate (%) 25.21
Particulars MAR 2022 (Values in Cr)
Revenue 123.55
Operating Expense 95.52
Net Profit 21.68
Net Profit Margin (%) 17.54
Earnings Per Share (EPS) 26.24
EBITDA 32.21
Effective Tax Rate (%) 25.12
Particulars MAR 2025 (Values in Cr)
Book Value / Share 185.64
ROE % 12.74
ROCE % 16.72
Total Debt to Total Equity 0.04
EBITDA Margin 18.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 161.49
ROE % 19.44
ROCE % 24.84
Total Debt to Total Equity 0.07
EBITDA Margin 21.96
Particulars MAR 2023 (Values in Cr)
Book Value / Share 133.00
ROE % 21.43
ROCE % 26.64
Total Debt to Total Equity 0.09
EBITDA Margin 21.85
Particulars MAR 2022 (Values in Cr)
Book Value / Share 104.36
ROE % 27.98
ROCE % 32.66
Total Debt to Total Equity 0.16
EBITDA Margin 26.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share 83.21
ROE % 58.75
ROCE % 59.10
Total Debt to Total Equity 0.37
EBITDA Margin 32.80
Particulars MAR 2025 (Values in Cr)
Book Value / Share 175.63
ROE % 13.36
ROCE % 17.49
Total Debt to Total Equity 0.04
EBITDA Margin 18.75
Particulars MAR 2024 (Values in Cr)
Book Value / Share 155.43
ROE % 20.18
ROCE % 25.70
Total Debt to Total Equity 0.07
EBITDA Margin 21.96
Particulars MAR 2023 (Values in Cr)
Book Value / Share 128.38
ROE % 21.86
ROCE % 27.12
Total Debt to Total Equity 0.09
EBITDA Margin 21.85
Particulars MAR 2022 (Values in Cr)
Book Value / Share 104.36
ROE % 28.52
ROCE % 34.30
Total Debt to Total Equity 0.13
EBITDA Margin 26.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share 79.65
ROE % 55.52
ROCE % 59.73
Total Debt to Total Equity 0.27
EBITDA Margin 34.46
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 5.55
Total Assets 174.70
Total Liabilities 174.70
Total Equity 153.40
Share Outstanding 0
Price to Book Ratio 2.40
Return on Assets (%) 12.32
Return on Capital (%) 13.85
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 3.28
Total Assets 157.02
Total Liabilities 157.02
Total Equity 133.45
Share Outstanding 0
Price to Book Ratio 3.40
Return on Assets (%) 15.82
Return on Capital (%) 17.67
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4.86
Total Assets 134.51
Total Liabilities 134.51
Total Equity 109.91
Share Outstanding 0
Price to Book Ratio 1.53
Return on Assets (%) 18.46
Return on Capital (%) 21.25
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 6.81
Total Assets 108.09
Total Liabilities 108.09
Total Equity 86.24
Share Outstanding 0
Price to Book Ratio 2.51
Return on Assets (%) 20.06
Return on Capital (%) 23.12
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.45
Total Assets 100.71
Total Liabilities 100.71
Total Equity 72.47
Share Outstanding 0
Price to Book Ratio 2.33
Return on Assets (%) 30.11
Return on Capital (%) 35.43
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 5.55
Total Assets 166.43
Total Liabilities 166.43
Total Equity 145.13
Share Outstanding 0
Price to Book Ratio 2.40
Return on Assets (%) 10.97
Return on Capital (%) 12.41
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.84
Total Assets 151.57
Total Liabilities 151.57
Total Equity 128.44
Share Outstanding 0
Price to Book Ratio 3.40
Return on Assets (%) 15.61
Return on Capital (%) 17.45
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 4.86
Total Assets 130.69
Total Liabilities 130.69
Total Equity 106.09
Share Outstanding 0
Price to Book Ratio 1.53
Return on Assets (%) 16.08
Return on Capital (%) 18.59
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 6.81
Total Assets 108.09
Total Liabilities 108.09
Total Equity 86.24
Share Outstanding 0
Price to Book Ratio 2.51
Return on Assets (%) 20.06
Return on Capital (%) 23.12
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 5.30
Total Assets 86.17
Total Liabilities 86.17
Total Equity 65.82
Share Outstanding 0
Price to Book Ratio 2.33
Return on Assets (%) 33.39
Return on Capital (%) 39.22
Particulars MAR 2025 (Values in Cr)
Net Income 24.36
Cash from Operations 26.11
Cash from Investing -9.87
Cash from Financing -7.96
Net change in Cash 2.28
Free Cash Flow 35.48
Particulars MAR 2024 (Values in Cr)
Net Income 31.52
Cash from Operations 29.01
Cash from Investing -20.30
Cash from Financing -2.86
Net change in Cash -2.02
Free Cash Flow 48.50
Particulars MAR 2023 (Values in Cr)
Net Income 28.11
Cash from Operations 28.67
Cash from Investing -20.72
Cash from Financing -2.40
Net change in Cash -1.95
Free Cash Flow 31.75
Particulars MAR 2022 (Values in Cr)
Net Income 28.96
Cash from Operations 29.15
Cash from Investing -16.43
Cash from Financing -4.09
Net change in Cash 1.50
Free Cash Flow 35.46
Particulars MAR 2021 (Values in Cr)
Net Income 42.70
Cash from Operations 29.96
Cash from Investing -4.86
Cash from Financing -10.59
Net change in Cash 3.61
Free Cash Flow 32.97
Particulars MAR 2025 (Values in Cr)
Net Income 24.36
Cash from Operations 26.11
Cash from Investing -9.87
Cash from Financing -7.96
Net change in Cash 2.28
Free Cash Flow 35.48
Particulars MAR 2024 (Values in Cr)
Net Income 31.52
Cash from Operations 29.01
Cash from Investing -20.30
Cash from Financing -2.86
Net change in Cash -2.02
Free Cash Flow 48.50
Particulars MAR 2023 (Values in Cr)
Net Income 28.11
Cash from Operations 28.67
Cash from Investing -20.72
Cash from Financing -2.40
Net change in Cash -1.95
Free Cash Flow 31.75
Particulars MAR 2022 (Values in Cr)
Net Income 28.96
Cash from Operations 29.15
Cash from Investing -16.43
Cash from Financing -4.09
Net change in Cash 1.50
Free Cash Flow 35.46
Particulars MAR 2021 (Values in Cr)
Net Income 38.76
Cash from Operations 27.74
Cash from Investing -4.17
Cash from Financing -9.80
Net change in Cash 3.60
Free Cash Flow 30.45
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 13.39 1.56 248.29 23.12 38.85
BLISS GVS PHARMA LTD. 438.10 35.56 3.89 4646.32 118.35 462.70
CIPLA LTD. 1388.80 29.47 3.25 112193.56 1165.55 1672.20
FERMENTA BIOTECH LTD. 338.80 14.94 2.45 997.12 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.40 22.66 4.17 248.29 23.12 38.85
AMRUTAJAN HEALTH LTD 557.75 25.00 4.35 1612.49 490.00 789.95
ASTRAZENECA PHARMA IND LT 8243.90 107.66 23.61 20609.75 7630.00 10653.05
BLISS GVS PHARMA LTD. 438.10 47.26 4.02 4646.32 118.35 462.70

TITAN BIOTECH LTD. shareholding pattern

Holding
44.19%
55.78%
0.02%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

TITAN BIOTECH LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
428.00 -0.10 redarrow
red-green-graph indicator
12 Bearish
4 Bullish
  • 5 Days 436.20
  • 26 Days 443.90
  • 10 Days 439.50
  • 50 Days 432.70
  • 12 Days 440.40
  • 100 Days 385.50
  • 20 Days 443.30
  • 200 Days 312.80
442.68 PIVOT
First Support 430.37 First Resistance 454.72 Second Support 418.33 Second Resistance 467.03 Third Support 406.02 Third Resistance 479.07
RSI 49.32 ADX 23.50 MACD -2.25 Williams % R -60.77 Commodity Channel Index (CCI) 2.64
Date 2026-06-12 Week 37335.00 Same Day 50371.00 Month 31197.00
1 Year -0.10 3 Year 0.50
Over 1 Month
-2.78% down
Over 1 Year
416.61% down
Over 3 Months
14.71% down
Over 3 Years
103.38% down
Over 6 Months
104.40% down
Over 5 Years
41.04% down

TITAN BIOTECH LTD. Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
19 Sep 2025 2.0 Final 19 Sep 2025 Equity shares
23 Sep 2024 2.0 Final 24 Sep 2024 Equity shares
22 Sep 2023 1.8 Final 22 Sep 2023 Equity shares
22 Sep 2022 1.5 Final 23 Sep 2022 Equity shares
16 Sep 2021 1.5 Final 08 Sep 2021 Equity shares
17 Sep 2020 1.0 Final 19 Sep 2020 Equity shares
19 Sep 2018 0.75 Final 22 Sep 2018 Equity shares
21 Sep 2017 0.75 Final 23 Sep 2017 Equity shares
22 Sep 2016 0.75 Final 26 Sep 2016 Equity shares
22 Sep 2015 0.75 Final 24 Sep 2015 Equity shares
18 Sep 2014 0.75 Final 22 Sep 2014 Equity shares
19 Sep 2013 0.75 Final 23 Sep 2013 Equity shares
22 Sep 2011 0.75 Final 26 Sep 2011 Equity shares
23 Sep 2010 0.5 Final 25 Sep 2010 Equity shares
Ex-Date Old FV NEW FV Record Date
20 Feb 2026 10.0 2.0 20 Feb 2026

Top Gainers

Top Losers

stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Titan Biotech Ltd?

Answer Field

Titan Biotech Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 428.00 as on Jun 19 2026 03:30 PM.

What is the Market Cap of Titan Biotech Ltd Share?

Answer Field

The market cap of Titan Biotech Ltd for NSE ₹ 0.00 & for BSE ₹ 1,768.40 as on Jun 19 2026 03:30 PM.

What is the 52 Week High and Low of Titan Biotech Ltd?

Answer Field

The 52 Week High and Low of Titan Biotech Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 555.65 and ₹ 74.73.

What is 1 year return for Titan Biotech Ltd?

Answer Field

The 1 year returns on the stock has been 405.06%.

What is the P/E Ratio of Titan Biotech Ltd Share?

Answer Field

As on Jun 19 2026 03:30 PM the price-to-earnings (PE) ratio for Titan Biotech Ltd share is 64.53.

What is the PB ratio of Titan Biotech Ltd Share?

Answer Field

As on Jun 19 2026 03:30 PM, the price-to-book (PB) ratio for Titan Biotech Ltd share is 41.34.

How to Buy Titan Biotech Ltd Share?

Answer Field

You can trade in Titan Biotech Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Titan Biotech Ltd Share on Bajaj Broking App?

Answer Field

To buy Titan Biotech Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Titan Biotech Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image
Get Free Demat Account*
+91
close-img
Authorise with OTP
Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|